A phase I, randomized, double-blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis.

Clin Exp Dermatol · 2021 · PMC7756278 · PMID 32767679

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A sensitivity analysis excluding these four participants increased the numerical difference between calcipotriol and the vehicle, but such a difference did not reach statistical significance (data not shown).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.